money moves

Exclusive: Houston sports tech startup raises $1.6M to make stadiums safer and more socially distant

Houston-based sEATz has raised funding to help scale to the demands as fans safely return to stadiums. Photo courtesy of sEATz

When COVID-19 hit and shut down major events including sports and entertainment, a Houston tech startup that created a platform for in-stadium food and merchandise delivery hit a huge obstacle.

However, what seemed like an insurmountable challenge became sEATz's biggest opportunity. As sports management teams start to envision bringing in more fans, they've realized they have to prioritizing limiting crowds and enabling social distancing. SEATz — with its in-seat ordering app and backend software — enables fans to stay seated and avoid lines.

"We really started seeing how integral our platform was going to be for the safe return for sports and entertainment," says Aaron Knape, CEO and co-founder of sEATz."When we started getting that momentum and traction with our clients, our investor base and perspective investor base got really excited."

And those excited investors allowed the startup to raise a second seed round of venture capital to the tune of $1.6 million. In September 2019, sEATz closed a $1.3 million seed round led by Houston-based Valedor Partners. Valedor again led this round, says Knape, and, while the plan was just to raise $1 million, the bar was raised to give the company even more funds to scale.

"We didn't want to just idle through COVID," Knape tells InnovationMap. "We see a tremendous opportunity to grow in the market and to expand the capabilities if the platform."

The funds will go toward marketing opportunities as well as tech development. including integrating with various points of service systems.

"We didn't pivot. We expanded our capabilities," Knape says on how sEATz was always focused on mitigating lines in sports and entertainment settings. "This will in all likelihood will make us a much stronger company coming out of COVID."

sEATz In-seat food delivery is going to be a must as fans return to stadiums safely. Courtesy of sEATz

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted